Newer β-Lactam/β-Lactamase inhibitor for multidrug-resistant gram-negative infections: Challenges, implications and...

Area of Science:

• Microbiology
• Public Health
• Infectious Diseases

Background:

• Antimicrobial resistance (AMR) poses a significant global health challenge, with increasing rates limiting treatment options.
• Beta-lactam antibiotics are crucial for Gram-negative infections but are threatened by diverse beta-lactamases.
• Development of beta-lactamase inhibitors is essential to overcome resistance mechanisms.

Purpose of the Study:

• To address the burden of antimicrobial resistance in India.
• To evaluate the role of newer beta-lactam/beta-lactamase inhibitor agents in the Indian context.
• To outline Indian Council of Medical Research interventions for combating drug resistance.

Main Methods:

• Review of the current scenario of AMR in India, including antimicrobial susceptibility and resistance mechanisms.
• Analysis of the use of beta-lactam/beta-lactamase inhibitors as carbapenem-sparing agents.
• Examination of national surveillance and infection control strategies.

Main Results:

• The study highlights the critical need for improved national surveillance systems in India.
• It emphasizes the appropriateness of newer beta-lactam/beta-lactamase inhibitor agents for the Indian scenario.
• Indian Council of Medical Research interventions are crucial for a national response to AMR.

Conclusions:

• There is an urgent need for country-specific newer agents to combat antimicrobial resistance in India.
• Enhanced national surveillance and infection control are vital for managing AMR.
• A multi-faceted approach involving newer agents and robust surveillance is required to fight AMR in India.